MXPA05005423A - Productos geneticos expresados de forma diferencial en tumores y su uso. - Google Patents

Productos geneticos expresados de forma diferencial en tumores y su uso.

Info

Publication number
MXPA05005423A
MXPA05005423A MXPA05005423A MXPA05005423A MXPA05005423A MX PA05005423 A MXPA05005423 A MX PA05005423A MX PA05005423 A MXPA05005423 A MX PA05005423A MX PA05005423 A MXPA05005423 A MX PA05005423A MX PA05005423 A MXPA05005423 A MX PA05005423A
Authority
MX
Mexico
Prior art keywords
nucleic acid
tumors
leu
antigen
cells
Prior art date
Application number
MXPA05005423A
Other languages
English (en)
Spanish (es)
Inventor
Sahin Ugur
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MXPA05005423A publication Critical patent/MXPA05005423A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
MXPA05005423A 2002-11-22 2003-11-21 Productos geneticos expresados de forma diferencial en tumores y su uso. MXPA05005423A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10254601A DE10254601A1 (de) 2002-11-22 2002-11-22 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PCT/EP2003/013091 WO2004047863A2 (de) 2002-11-22 2003-11-21 In tumoren differentiell exprimierte genprodukte und deren verwendung

Publications (1)

Publication Number Publication Date
MXPA05005423A true MXPA05005423A (es) 2005-08-03

Family

ID=32240310

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA05005423A MXPA05005423A (es) 2002-11-22 2003-11-21 Productos geneticos expresados de forma diferencial en tumores y su uso.
MX2012004983A MX344216B (es) 2002-11-22 2003-11-21 Productos geneticos expresados de forma diferencial en tumores y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012004983A MX344216B (es) 2002-11-22 2003-11-21 Productos geneticos expresados de forma diferencial en tumores y su uso.

Country Status (20)

Country Link
US (7) US7527933B2 (enExample)
EP (27) EP2399996B1 (enExample)
JP (7) JP2006516190A (enExample)
KR (7) KR101507976B1 (enExample)
CN (4) CN103381274B (enExample)
AU (2) AU2003282101B2 (enExample)
BR (1) BR0316435A (enExample)
CA (2) CA2505757A1 (enExample)
CY (1) CY1117786T1 (enExample)
DE (1) DE10254601A1 (enExample)
ES (2) ES2583754T3 (enExample)
HU (1) HUE027825T2 (enExample)
IL (7) IL168168A (enExample)
MX (2) MXPA05005423A (enExample)
NZ (4) NZ595896A (enExample)
PL (3) PL219018B1 (enExample)
PT (1) PT2400018T (enExample)
SG (3) SG2012077905A (enExample)
SI (1) SI2400018T1 (enExample)
WO (1) WO2004047863A2 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
DE10344799A1 (de) * 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2011256897B2 (en) * 2004-05-18 2013-09-19 Astellas Pharma Inc. Genetic products differentially expressed in tumors and the use thereof
WO2006025551A1 (ja) 2004-08-30 2006-03-09 Takeda Pharmaceutical Company Limited スクリーニング方法
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2014208256B2 (en) * 2005-11-24 2016-01-14 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
AU2016202322B2 (en) * 2005-11-24 2018-03-08 Astellas Pharma Inc. Monoclonal antibodies against claudin-18 for treatment of cancer
JP2009536313A (ja) 2006-01-11 2009-10-08 レインダンス テクノロジーズ， インコーポレイテッド ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法
ATE540750T1 (de) 2006-05-11 2012-01-15 Raindance Technologies Inc Mikrofluidische vorrichtung und verfahren
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
US9492518B2 (en) * 2006-10-04 2016-11-15 Dana-Farber Cancer Institute, Inc. Tumor immunity
US7951781B2 (en) * 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP1997832A1 (en) * 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2486409A1 (en) 2009-10-09 2012-08-15 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
CN110054692A (zh) 2009-10-23 2019-07-26 米伦纽姆医药公司 抗gcc抗体分子及其相关组合物和方法
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
EP2547695B1 (en) * 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Tumor vaccination involving a humoral immune response against self-protein cldn18.2
EP3447155A1 (en) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwich assays in droplets
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP3351641A1 (en) 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2714970B1 (en) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Enzyme quantification
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CN102526703B (zh) * 2012-01-18 2013-11-13 广东医学院司法鉴定中心 一种鼻咽癌相关易感基因yh1蛋白的制备方法及其应用
EP2823303A4 (en) 2012-02-10 2015-09-30 Raindance Technologies Inc MOLECULAR DIAGNOSTIC SCREENING TEST
ME03560B (me) 2012-04-27 2020-07-20 Millennium Pharm Inc MOLEKULI ANTI-GCC ANTITELA l NJIHOVA UPOTREBA U ISPITIVANJU OSETLJIVOSTI NA GCC-CILJANU TERAPIJU
EP3524693A1 (en) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digital analyte analysis
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK1209434A1 (en) 2012-11-13 2016-04-01 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
EP3105309B1 (en) 2014-02-13 2019-04-10 Basf Se Powder and granule, process for making such powder and granule, and use thereof
WO2015124138A1 (de) * 2014-02-20 2015-08-27 Rheinische Friedrich-Wilhelms-Universität Bonn Tumor-assoziierte antigene und genprodukte in der diagnose und therapie
WO2016149261A1 (en) * 2015-03-16 2016-09-22 Personal Genome Diagnostics, Inc. Systems and methods for analyzing nucleic acid
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3374386B1 (en) 2015-11-13 2024-05-29 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
CN105463094B (zh) * 2015-12-29 2018-09-07 北京泱深生物信息技术有限公司 直肠腺癌的诊治标记物
US11927591B2 (en) 2016-08-02 2024-03-12 Georgetown University Methods of identifying novel proteins and antigens in cancer cells
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US11525010B2 (en) * 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
CA3110593A1 (en) 2018-08-27 2020-03-05 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-claudin18.2 antibody and use thereof
EP3917564A4 (en) 2019-02-01 2022-12-21 NovaRock Biotherapeutics, Ltd. ANTI-CLAUDINE 18 ANTIBODIES AND THEIR METHODS OF USE
AU2020398045A1 (en) 2019-12-06 2022-06-09 Sotio Biotech A.S. Humanized CLDN18.2 antibodies
US20240034783A1 (en) 2019-12-23 2024-02-01 Sotio Biotech A.S. Tumor-specific claudin 18.2 antibodies
WO2021238831A1 (en) * 2020-05-25 2021-12-02 Mabspace Biosciences (Suzhou) Co., Limited Anti-cldn18.2 antibodies and diagnostic uses thereof
US20230323431A1 (en) * 2020-08-31 2023-10-12 World Biotech Regenerative Medical Group Limited Personalized Immunogenic Compositions and Methods for Producing and Using Same
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
PE20231561A1 (es) 2020-12-23 2023-10-03 Sotio Biotech A S Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2

Family Cites Families (245)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US4956556A (en) 1988-11-14 1990-09-11 Siemens Analytical X-Ray Instruments, Inc. Radiation scintillation detector
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
EP0507868A4 (en) 1989-12-27 1992-11-04 Us Commerce Diagnostic probe for detecting human stomach cancer
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1876241A3 (en) * 1996-01-11 2008-07-30 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
WO1998020143A1 (en) * 1996-11-05 1998-05-14 Abbott Laboratories Reagents and methods useful for detecting diseases of the lung
WO2000075327A1 (en) 1999-06-02 2000-12-14 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
US20030022298A1 (en) 1997-09-15 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030073129A1 (en) 1998-09-01 2003-04-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030008352A1 (en) 1997-09-18 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050196832A1 (en) 1997-09-18 2005-09-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030027272A1 (en) 1997-09-18 2003-02-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166104A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166110A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7160985B2 (en) * 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030040471A1 (en) 1998-04-29 2003-02-27 Watson James D. Compositions isolated from skin cells and methods for their use
US20030022835A1 (en) 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP3428441B2 (ja) 1998-05-15 2003-07-22 エーザイ株式会社 タイトジャンクション構成膜蛋白質クローディンファミリー
EP1082459A4 (en) * 1998-05-21 2002-09-25 Diadexus Inc DIAGNOSTIC, MONITORING AND STADIFICATION TECHNIQUE FOR LUNG CANCER
US7351543B2 (en) 1998-06-02 2008-04-01 Genentech, Inc. Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US7319008B2 (en) 1998-06-02 2008-01-15 Genentech, Inc. Nucleic acid underexpressed in melanoma
WO1999064452A1 (en) * 1998-06-11 1999-12-16 Smithkline Beecham Corporation Gpr35a receptor
US7339033B2 (en) 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
WO2000001821A2 (en) * 1998-07-02 2000-01-13 Incyte Pharmaceuticals, Inc. Neurotransmission associated proteins
CA2347656A1 (en) 1998-08-04 2000-02-17 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating lung cancer
US20050181478A1 (en) 1998-09-01 2005-08-18 Baker Kevin P. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6951921B2 (en) 1998-09-01 2005-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7026455B2 (en) 1998-09-01 2006-04-11 Genentech, Inc. Anti-pro 1343 antibodies
US20030082626A1 (en) 1998-09-01 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL141535A0 (en) 1998-09-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6143399A (en) 1998-09-16 2000-04-03 Zymogenetics Inc. Stomach polypeptide zsig28
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
HK1039783A1 (zh) 1998-10-06 2002-05-10 Curagen Corporation 新的分泌型蛋白和编码它们的多核苷
US7399834B2 (en) 1998-10-07 2008-07-15 Genentech, Inc. Anti-PRO1558 antibodies
EP1080209A2 (en) 1998-10-21 2001-03-07 Arch Development Corporation Methods of treatment of type 2 diabetes
JP2002530062A (ja) * 1998-10-28 2002-09-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １２個のヒト分泌タンパク質
US7026449B2 (en) 1999-01-05 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7507404B2 (en) 1999-03-08 2009-03-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2883600A (en) 1999-03-08 2000-09-28 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7232889B2 (en) 1999-03-08 2007-06-19 Genentech, Inc. PRO300 antibodies
AU768694B2 (en) 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
NZ527292A (en) 1999-03-23 2005-03-24 Genentech Inc Secreted and transmembrane polypeptides PRO1484 and nucleic acids encoding the same, with homology to an adipocyte complement-related protein
CA2383592A1 (en) 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
US20080286821A1 (en) 1999-05-14 2008-11-20 Eaton Dan L Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2215300A (en) 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
ATE448246T1 (de) 1999-06-15 2009-11-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
PT1185648E (pt) 1999-06-22 2007-06-29 Genentech Inc Métodos e composições para a inibição do crescimento de células neoplásicas.
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001012660A2 (en) * 1999-08-17 2001-02-22 Sagami Chemical Research Center HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU1205901A (en) 1999-10-14 2001-04-23 Board Of Trustees Of The University Of Arkansas, The Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof
EP1250426A2 (en) 1999-12-01 2002-10-23 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding same
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
CA2390685C (en) 2000-01-06 2008-04-22 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1251863A4 (en) * 2000-01-31 2005-03-02 Human Genome Sciences Inc 22 SEPARATE HUMAN PROTEINS
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030050231A1 (en) 2000-01-31 2003-03-13 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1259647A2 (en) * 2000-02-17 2002-11-27 Diadexus, Inc. Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
AU6802801A (en) * 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001090357A1 (en) 2000-05-24 2001-11-29 Genesis Research & Development Corporation Limited Compositions isolated from skin cells and methods for their use
EP1309620A2 (en) * 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP2004502414A (ja) * 2000-06-30 2004-01-29 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｂ７様ポリヌクレオチド、ポリペプチドおよび抗体
AU2001271589A1 (en) 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
EP1354040A2 (en) * 2000-07-20 2003-10-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EA007958B1 (ru) 2000-08-03 2007-02-27 Терапеутик Хьюман Поликлоналз Инк. ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ
AU2001284977B2 (en) 2000-08-15 2005-11-24 Immunex Corporation Claudin polypeptides
AU2001285047A1 (en) * 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
WO2002018576A2 (en) * 2000-08-28 2002-03-07 Diadexus, Inc. Compositions and methods relating to lung specific genes
CN1452633A (zh) 2000-09-08 2003-10-29 先灵公司 哺乳动物基因、相关试剂及方法
EP1326972A2 (en) * 2000-09-15 2003-07-16 Incyte Genomics, Inc. Transporters and ion channels
AU2001292728A1 (en) 2000-09-18 2002-03-26 Thomas Jefferson University Compositions and methods for identifying and targeting stomach and esophageal cancer cells
AU2002241730A1 (en) * 2000-10-26 2002-06-18 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2004535776A (ja) 2001-01-29 2004-12-02 フェイズ − １ モレキュラー トクシコロジー、インコーポレイテッド ラット毒性関連遺伝子及びその使用
JP3948702B2 (ja) 2001-02-14 2007-07-25 社団法人畜産技術協会 ウシのＣｌａｕｄｉｎ−１６欠損症タイプ２の遺伝子診断法
EP1412372A4 (en) * 2001-02-26 2005-08-24 Arena Pharm Inc ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G-PROTEIN COUPLED RECEPTORS
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
US20030152939A1 (en) 2001-04-09 2003-08-14 Glennda Smithson Novel secreted proteins and polynucleotides encoding them
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003000249A (ja) 2001-05-10 2003-01-07 Daiichi Fine Chemical Co Ltd クローディンによるＭＴ−ＭＭＰｓを介したｐｒｏＭＭＰ−２活性化
US20030108890A1 (en) * 2001-05-30 2003-06-12 Baranova Anna Vjacheslavovna In silico screening for phenotype-associated expressed sequences
CA2448112A1 (en) * 2001-06-05 2002-12-12 Exelixis Inc. Lces as modifiers of the p53 pathway and methods of use
EP1493028A4 (en) 2001-07-06 2006-06-14 Genentech Inc PHAGEN DISPLAY PRESENTED LIGANDS OF THE PDZ DOMAIN
WO2004045535A2 (en) 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1443951A4 (en) 2001-08-03 2006-05-03 Arbor Vita Corp MOLECULAR INTERACTIONS IN CELLS
US20030018173A1 (en) 2001-12-06 2003-01-23 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
AU2003240495A1 (en) 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
CA2501818C (en) 2002-10-10 2012-03-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical compositions directed to erb-b1 receptors
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1430902A1 (en) 2002-12-20 2004-06-23 Mondobiotech Laboratories Anstalt Pharmaceutical composition of interferon gamma with molecular diagnostics for the improved treatment of asthma bronchiale
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
JP5010281B2 (ja) 2003-05-31 2012-08-29 マイクロメット アクツィエン ゲゼルシャフト Ｅｐｃａｍに対する二重特異性抗体を含む薬学的組成物
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005032495A2 (en) 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
DE10354601B3 (de) 2003-11-21 2005-06-23 Chiropro Gmbh Gelenkprothese für Fingerglieder
WO2005052182A2 (en) 2003-11-26 2005-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method of analyzing plasma membrane protein content of cells
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005076939A2 (en) 2004-02-09 2005-08-25 University Of Kentucky Research Foundation Assay and method for diagnosing and treating alzheimer’s disease
EP1732582A2 (en) 2004-02-26 2006-12-20 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells
EP1745007A2 (en) 2004-04-16 2007-01-24 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
US20050255041A1 (en) 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2302393A1 (en) 2004-05-21 2011-03-30 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
WO2006023121A1 (en) 2004-07-27 2006-03-02 Ohio University Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in white adipose tissue (13)
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
FR2876705B1 (fr) 2004-10-19 2008-12-12 Biomerieux Sa Procede pour le diagnostic d'une intolerance a l'aspirine
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
WO2007005800A1 (en) 2005-06-30 2007-01-11 Abbott Laboratories Endoprosthesis having foot extensions
CA2613482A1 (en) 2005-07-01 2007-02-15 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of influenza
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007027867A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
ES2391573T3 (es) 2005-09-08 2012-11-27 Medinet Co., Ltd. Método para el tratamiento de activación de una célula presentadora de antígeno
DK1934615T3 (da) 2005-09-19 2014-07-14 Janssen Diagnostics Llc Fremgangsmåder og materialer til identificering af oprindelsen af et karcinom med ukendt primær oprindelse
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PL1976880T3 (pl) 2005-12-21 2017-01-31 Amgen Research (Munich) Gmbh Kompozycje farmaceutyczne odporne na rozpuszczalny cea
EP1981539B1 (en) 2006-02-09 2014-07-23 Amgen Research (Munich) GmbH Treatment of metastatic breast cancer
CA2637988A1 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
EP1999151A2 (en) 2006-03-29 2008-12-10 Genentech, Inc. Diagnostics and treatments for tumors
US20100129929A1 (en) 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US20100004253A1 (en) 2006-09-19 2010-01-07 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008043561A2 (en) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
CA2671194A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
EP2125034A4 (en) 2007-02-01 2010-01-27 Veridex Llc METHOD AND MATERIALS FOR IDENTIFYING THE ORIGIN OF A CARCINOMA OF UNKNOWN PRIMARY ORIGIN
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008154333A2 (en) 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2008152822A1 (ja) 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
US20100292303A1 (en) 2007-07-20 2010-11-18 Birrer Michael J Gene expression profile for predicting ovarian cancer patient survival
WO2009035497A2 (en) 2007-08-08 2009-03-19 Savidge Tor C Disease related cysteine modifications and uses thereof
EP2036987A1 (en) 2007-09-17 2009-03-18 Siemens Healthcare Diagnostics GmbH Molecular markers for tumor cell content in tissue samples
CN101801370B (zh) 2007-09-19 2013-06-12 三得利控股株式会社 含有芝麻素类和花生四烯酸类的组合物
CA2702180A1 (en) 2007-10-12 2009-04-16 Peter Humphries Method for opening tight junctions
US8563515B2 (en) 2007-11-19 2013-10-22 The Regents Of The University Of Colorado, A Body Corporate Tight junction protein modulators and uses thereof
JP5596559B2 (ja) 2008-01-28 2014-09-24 メディミューン リミテッド 安定化アンジオポエチン２抗体とその用途
AU2009255599A1 (en) 2008-06-02 2009-12-10 Nsabp Foundation, Inc. Identification and use of prognostic and predictive markers in cancer treatment
US7989597B2 (en) 2008-06-20 2011-08-02 Oklahoma Medical Research Foundation Immunogenic memapsin 2 β-secretase peptides and methods of use
JP2011529172A (ja) 2008-07-25 2011-12-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング モノクローナル抗体によるレセプター結合飽和を測定する方法
US20110190380A1 (en) 2008-10-23 2011-08-04 Elena Feinstein Methods for delivery of sirna to bone marrow cells and uses thereof
CN101381524A (zh) 2008-10-24 2009-03-11 南开大学 单层氧化石墨与水溶性高分子增强复合材料
RS53980B1 (sr) 2008-11-07 2015-10-30 Amgen Research (Munich) Gmbh Tretiranje akutne limfoblastne leukemije kod dece
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
GB0904957D0 (en) 2009-03-23 2009-05-06 Univ Erasmus Medical Ct Tumour gene profile
US20120028816A1 (en) 2009-03-31 2012-02-02 Warren Stephen T Methods and systems for screening for and diagnosing dna methylation associated with autism spectrum disorders
CN101584860A (zh) 2009-04-27 2009-11-25 西安杰诺瓦生物科技有限公司 重组人Claudin18.2肿瘤疫苗及其制备方法
WO2010141093A2 (en) 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
AU2010302955A1 (en) 2009-10-01 2012-05-17 Chipdx Llc System and method for classification of patients
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2011068839A1 (en) 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
WO2011090005A1 (ja) 2010-01-19 2011-07-28 協和発酵キリン株式会社 大腸癌の治療用医薬および治療方法
EP2547695B1 (en) 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Tumor vaccination involving a humoral immune response against self-protein cldn18.2
EP2366709A1 (en) 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
US8945847B2 (en) 2010-05-24 2015-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for ascertaining biosafety of an agent
CA2801107A1 (en) 2010-06-07 2011-12-15 F. Hoffman-La Roche Ag Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US20130157891A1 (en) 2010-06-24 2013-06-20 Xiao-Jun Li Organ specific diagnostic panels and methods for identification of organ specific panel proteins
WO2012070014A2 (en) 2010-11-26 2012-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells
AU2012206163B2 (en) 2011-01-12 2013-11-14 Morinaga Milk Industry Co., Ltd. Method for screening for diet providing production of milk having immunoregulatory action
DE102011005235B4 (de) 2011-03-08 2017-05-24 Sirs-Lab Gmbh Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014025199A2 (ko) 2012-08-09 2014-02-13 주식회사 한독 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014025198A2 (ko) 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
WO2014031859A2 (en) 2012-08-24 2014-02-27 University Of Utah Research Foundation Compositions and methods relating to blood-based biomarkers of breast cancer
US20140073524A1 (en) 2012-09-07 2014-03-13 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (ptsd)
US9856532B2 (en) 2012-09-07 2018-01-02 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (PTSD)
HK1209434A1 (en) 2012-11-13 2016-04-01 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6241403B2 (ja) 2014-10-24 2017-12-06 横浜ゴム株式会社 リン酸変性ポリマー

Also Published As

Publication number Publication date
IL201278A0 (en) 2011-08-01
KR101483736B1 (ko) 2015-01-16
SG10201705641SA (en) 2017-08-30
EP2399995A2 (de) 2011-12-28
HUE027825T2 (en) 2016-11-28
KR101551621B1 (ko) 2015-09-08
EP2399997A3 (de) 2012-08-08
EP2400017A3 (de) 2012-05-02
CA2505757A1 (en) 2004-06-10
CA3000243C (en) 2023-01-03
NZ595896A (en) 2013-03-28
SI2400018T1 (sl) 2016-08-31
EP2400007A3 (de) 2012-07-25
EP2400006A2 (de) 2011-12-28
EP2399996A2 (de) 2011-12-28
AU2003282101A1 (en) 2004-06-18
EP2400014A3 (de) 2012-05-02
JP2010178740A (ja) 2010-08-19
EP2400004A2 (de) 2011-12-28
IL168168A (en) 2014-09-30
NZ578130A (en) 2011-02-25
WO2004047863A2 (de) 2004-06-10
CN1714150A (zh) 2005-12-28
US20150337052A1 (en) 2015-11-26
US20060035852A1 (en) 2006-02-16
US8586047B2 (en) 2013-11-19
EP2400012A2 (de) 2011-12-28
EP2399998A2 (de) 2011-12-28
JP2016104800A (ja) 2016-06-09
EP2400016A3 (de) 2012-05-02
US8637012B2 (en) 2014-01-28
JP5726422B2 (ja) 2015-06-03
CN106581694A (zh) 2017-04-26
KR20150027313A (ko) 2015-03-11
EP2400011A2 (de) 2011-12-28
EP2400003A2 (de) 2011-12-28
PL392311A1 (pl) 2010-11-22
EP2400004A3 (de) 2012-08-01
JP6182127B2 (ja) 2017-08-16
EP3348570A1 (de) 2018-07-18
NZ590225A (en) 2012-07-27
SG180019A1 (en) 2012-05-30
US20170320963A1 (en) 2017-11-09
EP2399995A3 (de) 2012-08-08
JP2006516190A (ja) 2006-06-29
KR20050083962A (ko) 2005-08-26
KR101507976B1 (ko) 2015-04-07
PL219043B1 (pl) 2015-03-31
CN103381274A (zh) 2013-11-06
US20090155817A1 (en) 2009-06-18
EP2400008A2 (de) 2011-12-28
EP2400001B1 (de) 2018-02-28
US8088588B2 (en) 2012-01-03
EP2400003A3 (de) 2012-08-01
WO2004047863A3 (de) 2005-01-06
US20140186338A1 (en) 2014-07-03
US7527933B2 (en) 2009-05-05
IL231296A0 (en) 2014-04-30
JP2015063531A (ja) 2015-04-09
IL231294A0 (en) 2014-04-30
HK1165480A1 (zh) 2012-10-05
EP2399999A2 (de) 2011-12-28
JP2011136999A (ja) 2011-07-14
PL219018B1 (pl) 2015-02-27
IL201278A (en) 2014-09-30
JP5904478B2 (ja) 2016-04-13
EP2400006A3 (de) 2012-07-25
EP2400001A2 (de) 2011-12-28
EP2400013A2 (de) 2011-12-28
EP2400018B1 (de) 2016-05-04
MX344216B (es) 2016-12-07
EP2400012A3 (de) 2012-04-11
EP2400011A3 (de) 2012-07-25
CN1714150B (zh) 2011-03-02
EP2400014A2 (de) 2011-12-28
EP2400005A3 (de) 2012-08-01
EP2400018A3 (de) 2012-05-02
PL377240A1 (pl) 2006-01-23
AU2010202440A1 (en) 2010-07-01
AU2010202440B2 (en) 2012-11-01
EP2400009A2 (de) 2011-12-28
EP2400018A2 (de) 2011-12-28
CN103381274B (zh) 2016-08-03
KR101604788B1 (ko) 2016-03-18
JP2013046626A (ja) 2013-03-07
EP2400009A3 (de) 2012-07-25
EP2400010A3 (de) 2012-07-25
NZ539649A (en) 2009-09-25
KR20120006072A (ko) 2012-01-17
EP2400015A3 (de) 2012-04-18
EP2400019A3 (de) 2012-06-06
ES2583754T3 (es) 2016-09-22
EP2400000A2 (de) 2011-12-28
BR0316435A (pt) 2005-10-11
CA3000243A1 (en) 2004-06-10
EP2399996A3 (de) 2012-07-25
CN101966337A (zh) 2011-02-09
PL219093B1 (pl) 2015-03-31
SG2012077905A (en) 2017-04-27
EP2400008A3 (de) 2012-07-25
EP1563068B1 (de) 2018-04-25
IL231297A0 (en) 2014-04-30
EP2400002A2 (de) 2011-12-28
EP2399998A3 (de) 2012-07-25
ES2675785T3 (es) 2018-07-12
EP1563068A2 (de) 2005-08-17
US20120258091A1 (en) 2012-10-11
EP2399999A3 (de) 2012-07-25
EP2399996B1 (de) 2017-09-06
EP2400005A2 (de) 2011-12-28
EP2400000A3 (de) 2012-07-25
KR20130135402A (ko) 2013-12-10
US20090208498A1 (en) 2009-08-20
EP2399997A2 (de) 2011-12-28
JP2017206551A (ja) 2017-11-24
EP2400002A3 (de) 2012-08-01
EP2400015A2 (de) 2011-12-28
KR20170031804A (ko) 2017-03-21
PT2400018T (pt) 2016-08-02
EP2400007A2 (de) 2011-12-28
DE10254601A1 (de) 2004-06-03
PL392310A1 (pl) 2010-11-22
EP2400017A2 (de) 2011-12-28
KR20140114464A (ko) 2014-09-26
CY1117786T1 (el) 2017-05-17
IL231298A0 (en) 2014-04-30
EP2400013A3 (de) 2012-04-11
US10414824B2 (en) 2019-09-17
AU2003282101B2 (en) 2010-03-11
KR20120123592A (ko) 2012-11-08
KR101718117B1 (ko) 2017-03-20
EP2400001A3 (de) 2012-08-01
EP2400016A2 (de) 2011-12-28
EP2400019A2 (de) 2011-12-28
IL231295A0 (en) 2014-04-30
EP2400010A2 (de) 2011-12-28

Similar Documents

Publication Publication Date Title
CA3000243C (en) Genetic products differentially expressed in tumors and the use thereof
CA2563666C (en) Differentially expressed claudin-18 variants in tumors and use thereof
AU2016203425C1 (en) Genetic products differentially expressed in tumors and the use thereof
US20040249145A1 (en) Cell adhesion-mediating proteins and polynucleotides encoding them
HK1165462A (en) In tumours differentially expressed gene products and use of the same
HK1165485A (en) In tumours differentially expressed gene products and use of the same
HK1165473A (en) In tumours differentially expressed gene products and use of the same
HK1165476A (en) In tumours differentially expressed gene products and use of the same
HK1165479A (en) In tumours differentially expressed gene products and use of the same

Legal Events

Date Code Title Description
FG Grant or registration